Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma
Open Access
- 15 March 2008
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 19 (7) , 1331-1335
Abstract
Background: To evaluate the clinical outcome of patients with relapsed or refractory follicular lymphoma treated with immunochemotherapy, in vivo purging and high-dose therapy with autotransplant. Patients and methods: Sixty-four patients were enrolled in the trial. Primary end point was progression-free survival (PFS). Secondary end points were the in vivo purging effect on stem-cell harvest and the impact of molecular response on the outcome. Results: At enrollment, 59% of patients were PCR+ for bcl-2 rearrangement in bone marrow (PCR-informative). After the immunochemotherapy, before mobilization, 97% obtained complete response or partial response and 87% of patients informative for bcl-2 were molecularly negative. Sixty-one patients proceeded to in vivo purging and peripheral blood stem cell (PBSC) mobilization with rituximab and high-dose AraC. The median number of CD34+ cells collected was 16.6 × 106/kg. Of 33 PCR-informative patients, the harvests resulted in PCR− in all. Fifty-eight patients received high-dose therapy and autotransplant of in vivo purged PBSC. After a median follow-up of 3.5 years, 41 patients are in complete remission. Five-year PFS is 59%. Conclusion: This study demonstrates that patients with advanced relapsed or refractory follicular lymphoma treated with immunochemotherapy, in vivo purging and autotransplant may obtain long-lasting PFS. In bcl-2-positive patients, in vivo purging allows the harvest of lymphoma-free PBSC. Absence of the bcl-2 rearrangement after autotransplant is associated with persistent clinical remission.Keywords
This publication has 27 references indexed in Scilit:
- Myeloablative Therapy With Autologous Bone Marrow Transplantation for Follicular Lymphoma at the Time of Second or Subsequent Remission: Long-Term Follow-UpJournal of Clinical Oncology, 2007
- Long-Term Follow-Up of Indolent Lymphoma Patients Treated With High-Dose Sequential Chemotherapy and Autografting: Evidence That Durable Molecular and Clinical Remission Frequently Can Be Attained Only in Follicular SubtypesJournal of Clinical Oncology, 2004
- High-Dose Therapy Improves Progression-Free Survival and Survival in Relapsed Follicular Non-Hodgkin’s Lymphoma: Results From the Randomized European CUP TrialJournal of Clinical Oncology, 2003
- Intensive therapies in follicular non-Hodgkin lymphomasBlood, 2002
- Long-Term Follow-Up of Autologous Bone Marrow Transplantation in Patients With Relapsed Follicular LymphomaBlood, 1999
- Immunomagnetic bone marrow (BM) and peripheral blood progenitor cell (PBPC) purging in follicular lymphoma (FL)Bone Marrow Transplantation, 1999
- Use of the polymerase chain reaction and direct sequencing analysis to detect cells with the t(14;18) in autologous bone marrow from patients with follicular lymphoma, before and after in vitro treatmentBone Marrow Transplantation, 1998
- Purging Peripheral Blood Progenitor Cell Grafts from Lymphoma Cells: Quantitative Comparison of Immunomagnetic CD34 + Selection SystemsStem Cells, 1997
- Comparative Preclinical Study of Three Bone Marrow Purging Methods Using PCR Evaluation of Residual t(14;18) Lymphoma CellsLeukemia & Lymphoma, 1996
- Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphomaBlood, 1993